All Circulars (27800)
Browse all regulatory circulars from India’s major stock exchanges and market regulator. Navigate by source using the buttons below or explore individual circulars in the grid.
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BSE announces trading in Rights Entitlements (REs) for renunciation of Padam Cotton Yarns Limited, effective March 2, 2026, with the rights … | |||||||||||||||
BSE announces trading in Rights Entitlements (REs) for renunciation of Padam Cotton Yarns Limited, effective March 2, 2026, with the rights issue open from March 2 to March 9, 2026.
| |||||||||||||||
BSE announces commencement of trading in Rights Entitlements (REs) for Padam Cotton Yarns Limited from March 2, 2026, with renunciation … | |||||||||||||||
BSE announces commencement of trading in Rights Entitlements (REs) for Padam Cotton Yarns Limited from March 2, 2026, with renunciation period running March 2–4, 2026, settled on T+1 trade-for-trade basis.
| |||||||||||||||
BSE permits trading in Rights Entitlements (REs) for renunciation of Padam Cotton Yarns Limited from March 2 to March 4, 2026, with the … | |||||||||||||||
BSE permits trading in Rights Entitlements (REs) for renunciation of Padam Cotton Yarns Limited from March 2 to March 4, 2026, with the Rights Issue open from March 2 to March 9, 2026.
| |||||||||||||||
BSE notifies trading members that Nexome Capital Markets Limited has fixed March 5, 2026 as the record date for a rights issue of equity … | |||||||||||||||
BSE notifies trading members that Nexome Capital Markets Limited has fixed March 5, 2026 as the record date for a rights issue of equity shares at Rs. 75/- per share (1 share for every 2 held).
| |||||||||||||||
BSE notifies trading members that Nexome Capital Markets Limited has fixed March 5, 2026 as the record date for a rights issue offering 1 … | |||||||||||||||
BSE notifies trading members that Nexome Capital Markets Limited has fixed March 5, 2026 as the record date for a rights issue offering 1 new equity share for every 2 held at Rs. 75 per share (Rs. 10 face value + Rs. 65 premium).
| |||||||||||||||
NEXOME CAPITAL MARKETS LIMITED (BSE: 508905) has fixed a record date of 05 March 2026 for a rights issue offering 1 new equity share for … | |||||||||||||||
NEXOME CAPITAL MARKETS LIMITED (BSE: 508905) has fixed a record date of 05 March 2026 for a rights issue offering 1 new equity share for every 2 shares held at Rs. 75/- per share (face value Rs. 10/- at a premium of Rs. 65/-).
| |||||||||||||||
Nexome Capital Markets Limited has fixed March 5, 2026 as the record date for its rights issue, offering 1 equity share for every 2 held at … | |||||||||||||||
Nexome Capital Markets Limited has fixed March 5, 2026 as the record date for its rights issue, offering 1 equity share for every 2 held at Rs 75/- per share (Rs 10 face value + Rs 65 premium). Trading in equity shares will be on an ex-rights basis from the same date.
| |||||||||||||||
SEBI issues a completion certificate for Recovery Certificate No. 6648 of 2023 against Sadanand Prayag Mishra (PAN: AFVPM2400E) in the … | |||||||||||||||
SEBI issues a completion certificate for Recovery Certificate No. 6648 of 2023 against Sadanand Prayag Mishra (PAN: AFVPM2400E) in the matter of Shreekrishna Biotech Limited, signifying successful recovery of dues.
| |||||||||||||||
SEBI issues a completion certificate confirming that Recovery Certificate No. 7930 of 2024 against Restock Research (Proprietor: Raj Kumar … | |||||||||||||||
SEBI issues a completion certificate confirming that Recovery Certificate No. 7930 of 2024 against Restock Research (Proprietor: Raj Kumar Kushwah, PAN: BWZPK7725C) has been fully satisfied.
| |||||||||||||||
SEBI issues enforcement order against Arcotech Limited and 13 related entities for alleged fund diversion of Rs.14.15 crores, fictitious … | |||||||||||||||
SEBI issues enforcement order against Arcotech Limited and 13 related entities for alleged fund diversion of Rs.14.15 crores, fictitious transactions, and misrepresentation of financial statements across FY 2016-17 to 2020-21.
| |||||||||||||||